HOME >> BIOLOGY >> NEWS
FDA grants Accentia Biopharmaceuticals...

Tampa, Fla. --Accentia Biopharmaceuticals, Inc. (Nasdaq:ABPI) has been notified that the U.S. Food and Drug Administration (FDA) granted Fast Track status to SinuNaseTM, the Company's intranasal Amphotericin B formulation. To the best of the Company's knowledge, SinuNase is the first and only drug candidate for chronic sinusitis (CS) to receive Fast Track status from the FDA.

Under the FDA Modernization Act of 1997, a new drug may be designated "Fast Track" provided the agency feels that the drug candidate has the potential to address unmet medical needs by treating serious or life-threatening conditions. With Fast Track status for SinuNase, Accentia is now eligible to submit a new drug license application (NDA) on a rolling basis, allowing the FDA to review sections of the NDA in advance of receiving Accentia's full submission, and permitting Accentia to apply for expedited review of its NDA.

Frank E. O'Donnell, Jr., M.D., Accentia's Chairman and CEO, commented: "Chronic sinusitis represents a substantial unmet clinical need, causing significant morbidity and expense. There is no approved pharmaceutical for the treatment of chronic sinusitis, despite 31 million affected patients in the U.S. alone, and about 500,000 patients who resort to sinus surgery each year in an attempt to control their chronic symptoms . These patients have chronic obstruction of the sinuses, which predisposes them to acute sinusitis, a bacterial super-infection for which more than 40 million antibiotic prescriptions are dispensed annually. The healthcare cost of chronic sinusitis is estimated at greater than $5 billion a year."

Accentia is preparing to commence its Phase 3 placebo-controlled clinical trial with SinuNase to treat post-surgical patients suffering from recurrent CS. The study is intended to be a four-month double-blinded comparison of symptomatic relief in patients randomized for treatment with either SinuNase or a placebo control.
'"/>

Contact: Adam Holdsworth
aholdsworth@investorrelationsgroup.com
212-825-3210
The Investor Relations Group
12-Apr-2006


Page: 1 2 3 4

Related biology news :

1. Gilbert Foundation and American Fed for Aging Research award grants on Alzheimers disease
2. New grants bolster efforts to generate faster and cheaper tools for DNA sequencing
3. New amfAR research grants to optimize HIV treatment
4. Ancient Etruscans were immigrants from Anatolia, or what is now Turkey
5. Berkeley Lab Life Sciences division awarded NIH grants for fruit fly, nematode studies
6. UAF researchers garner $6.5 million in NSF grants
7. Burroughs Wellcome fund awards $8.25 million in grants to physician-scientists
8. UCLA scientists garner 7 grants to fund leading-edge embryonic stem cell research
9. New medications, cancer diagnosis goals of UH engineers with $1M in grants
10. Barrow receives two grants worth a total of 900,000 from the ABRC
11. Kentucky first state to match federal SBIR-STTR Phase 1 and Phase 2 grants

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/22/2020)... ... July 21, 2020 , ... USDM Life Sciences , ... announces a new solution to manage regulated workloads on Microsoft Azure. , Regulated ... stack complies with FDA and global regulations. USDM's new managed service for regulated ...
(Date:7/18/2020)... ... 2020 , ... Commercial launch readiness is a critical stage in a product ... or vaccine, the global economic downturn will only increase price pressures overall for the ... capturing full value from every product launch is critical. However, history shows that only ...
(Date:7/10/2020)... ... ... Today CJ BIO announced the first in a series of Food Ingredient MasterClass ... is revolutionizing ingredient mixes, nutritional content and flavor profiles across a range of savory ... at11:00 AM (CDT) during SHIFT20, the virtual edition of the IFT Annual Meeting & ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 30, 2020 , ... ... sciences industry, today announced the release of its signature product called Beacon ... Liaisons (MSLs) and other field medical professionals. , Beacon helps MSLs ...
(Date:7/18/2020)... MILWAUKEE (PRWEB) , ... July 16, 2020 , ... “We ... at Third Wave Bioactives. “It’s the only technology of its kind on the market ... flavor of onions with the protective capacity of traditional cultured ingredients, creating a natural ...
(Date:7/10/2020)... ... July 08, 2020 , ... Bode Technology, a ... laboratory operations through its COVID-19 testing service, Bode-CARES . Bode-CARES combines high-volume ... Bode-CARES provides a turnkey solution that includes a comprehensive collection and virus-management ...
(Date:7/10/2020)... Mass. (PRWEB) , ... July 09, 2020 , ... ... approaches to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., ... team and oversee the clinical development of Sentien’s lead product, SBI-101. Dr. ...
Breaking Biology Technology:
Cached News: